-+ 0.00%
-+ 0.00%
-+ 0.00%
Huabei Pharmaceutical (600812.SH): A total of 240 varieties are included in the 2026 National Health Insurance Catalogue
Share
Listen to the news

According to the Zhitong Finance App, North China Pharmaceutical (600812.SH) announced that the company and its subsidiaries included 240 varieties in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)” (“Medical Insurance Catalogue”), of which 113 are Class A and 127 Class B.

The company's main products include injectable piperacillin sodium and tazobactam sodium, injectable norvancomycin hydrochloride, amoxicillin capsules, etc. continue to be included in this medical insurance catalogue. There are 7 varieties newly selected in the medical insurance catalogue, namely olmativir injections, tacrolimus capsules, cefpropene tablets, lettemovir injections, roxastat capsules, toluximab tablets, and nadroparin calcium injections. Among them, the company's first-class innovative drug oltimutimivir injections passed medical insurance negotiations Included in this medical insurance catalogue. Due to this medical insurance catalogue adjustment, the company has not transferred any products.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending